Beleggen.nl
Uitgebreid zoeken
Markt MonitorMarkt Monitor

BioPharma Terug naar discussie overzicht

INSM - Insmed - Deel 13

1.310 Posts
Pagina: «« 1 ... 5 6 7 8 9 ... 66 »» | Laatste | Omlaag ↓
  2. [verwijderd] 7 februari 2007 21:48

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    Markweb4 schreef:

    Er wordt nu wel serieus gekocht.

    Koers
    Laatste 1,10
    Laatste volume 1.000
    Tijd 21:45
    +/- 0,16 17,51%
    Volume 4.443.719

    inderdaad zeer sterk vervolg
    technisch is ie vandaag ook rond 0,97 een buy signaal geworden
  3. [verwijderd] 7 februari 2007 21:54

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    ...wij weten wat hier werkt!

    The associated features of lipodystrophy - and again, this begins to sound to me like a syndrome - insulin resistant diabetes and hypertriglyceridemia are typically associated with these non-HIV associated lipodystrophy. As I pointed out, fat accumulation can occur in unaffected areas, such as the head and neck. For the infectious disease individuals in the audience, partial lipodystrophy has been reported following febrile illnesses associated with collagen or vascular diseases and deficiency in C3. Now the HIV world became alerted to lipodystrophy in this report in AIDS by Carr and Cooper from Australia. Illustrated here is a patient they describe as typically losing fat in the face. You can see this loss of fat in the sub-zygomatic area. It’s fairly dramatic. This individual also had lost fat in the periphery but a tendency to retain fat, or maybe even accumulate it, in the abdominal area. They actually found this kind of pattern, they said, in about 65% of 116 patients that they surveyed in their clinic who were on protease inhibitors and only 3 or 4% of patients who were not on protease inhibitors. That is really an astounding finding. So we have gone now to try to get an idea of prevalence of this complaint and reviewed this six or seven or eight reports that have appeared either at Geneva in abstract or in a couple of papers that have been published. What strikes us as really amazing here is the difference in prevalence estimates. Ranging from 2% in one fairly large population - 272 chart reviewed - up to 65 or 75% from the group in Australia. I think that probably the truth lies somewhere in between, but where it is and how close it is to the lower or higher figure, we don’t know. There was just a meeting in Chicago and planning for a NIH study. The ACTG is going to do a prevalence study and is probably going to take a hard look at several thousand patients to try to get a feeling for how frequently this problem occurs. My final slide is, I think, a list of issues. I think we need to develop the uniform case definition of fat redistribution disorders. Is it one syndrome or overlaps of several? We need to identify the mechanisms underlying these metabolic and body composition changes. The relationship, if any, to specific anti-retroviral regimens, and what their clinical sequelae are. Should we be worried about this? People are actually stopping therapy because of their concerns about their lipid profiles, obviously in people who are in effective anti-retrovirals that is not something that we want to recommend. And finally we need to define the optimal management. I can say that there have been a couple of case reports or anecdotal reports of the use of growth hormone, of anabolic steroids, of insulin sensitizing drugs like troglitazone, or metformin. And yet no careful studies have yet been done to really let us know whether these are going to be effective and safe. There are reasons that for example growth hormone, has to be given with care because of its tendency to exacerbate hyperlipidemia and insulin resistance, which is known from the non-HIV world.
    rxdic.com/publications-and-articles/m...

    Geluk, F.
  4. Mark__ 7 februari 2007 22:01

    • Mark__

      Lid sinds: 13 feb 2006

      Laatste bezoek: 17 aug 2023

    • Aanbevelingen

      Ontvangen: 24

      Gegeven: 12

    •    Aantal posts: 1.299

    Aardig slot:

    Koers
    Laatste 1,11
    Laatste volume 7.500
    Tijd 22:00
    +/- 0,17 18,59%
    Volume 4.757.066
  7. prrrrr 7 februari 2007 22:08

    • prrrrr

      Lid sinds: 06 mrt 2005

      Laatste bezoek: 12 sep 2024

    • Aanbevelingen

      Ontvangen: 41

      Gegeven: 8

    •    Aantal posts: 2.350

    M.A.D.W. schreef:

    sethonno schreef:

    en nu nog 10 van die dagen dat zou leuk zijn.

    Ik heb je aanbevolen, dat zou ik ook leuk vinden! lol

    dan kan jij stoppen met werken. het is je gegunt.
  12. [verwijderd] 7 februari 2007 22:55

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Shit, khad hier wat kunnen verdienen! :) Shorters zeker. Gefeliciteerd mannen (en meisjes natuurlijk) Blijft echter waakzaam (maarde despereert nooit).
    Moi Beur
  16. [verwijderd] 8 februari 2007 09:55

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    magie228 schreef:

    waarom stijgt het? ik zie geen nieuws!
    Shorts die coveren, of grote durfkapitalisten die nu een positie innemen die speculeren op geen injunction. Plus vergeet niet dat we binnen 2 weken nieuws van de EMEA kunnen verwachten. Dus sta niet raar te kijken als we zo weer op 1,50 staan.
1.310 Posts
Pagina: «« 1 ... 5 6 7 8 9 ... 66 »» | Laatste |Omhoog ↑

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 466 7.001
AB InBev 2 5.481
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.582 51.200
ABO-Group 1 22
Acacia Pharma 9 24.692
Accell Group 151 4.132
Accentis 2 264
Accsys Technologies 23 10.526
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 188
ADMA Biologics 1 34
Adomos 1 126
AdUX 2 457
Adyen 14 17.649
Aedifica 3 901
Aegon 3.258 322.656
AFC Ajax 538 7.086
Affimed NV 2 6.287
ageas 5.844 109.885
Agfa-Gevaert 14 2.048
Ahold 3.538 74.293
Air France - KLM 1.025 34.997
AIRBUS 1 11
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 467 13.036
Alfen 16 24.330
Allfunds Group 4 1.468
Almunda Professionals (vh Novisource) 651 4.251
Alpha Pro Tech 1 17
Alphabet Inc. 1 405
Altice 106 51.198
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.486 114.813
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.835 242.722
AMG 971 133.079
AMS 3 73
Amsterdam Commodities 305 6.686
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 485
Antonov 22.632 153.605
Aperam 92 14.931
Apollo Alternative Assets 1 17
Apple 5 380
Arcadis 252 8.731
Arcelor Mittal 2.033 320.572
Archos 1 1
Arcona Property Fund 1 286
arGEN-X 17 10.288
Aroundtown SA 1 219
Arrowhead Research 5 9.716
Ascencio 1 26
ASIT biotech 2 697
ASMI 4.108 39.081
ASML 1.766 106.029
ASR Nederland 21 4.451
ATAI Life Sciences 1 7
Atenor Group 1 470
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 32 13.610
Axsome Therapeutics 1 177
Azelis Group 1 64
Azerion 7 3.390